SHR-1314 + Placebo
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate-to-severe Chronic Plaque Psoriasis
Conditions
Moderate-to-severe Chronic Plaque Psoriasis
Trial Timeline
Dec 15, 2017 → Aug 31, 2020
NCT ID
NCT03463187About SHR-1314 + Placebo
SHR-1314 + Placebo is a phase 1/2 stage product being developed by Jiangsu Hengrui Medicine for Moderate-to-severe Chronic Plaque Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03463187. Target conditions include Moderate-to-severe Chronic Plaque Psoriasis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04839016 | Phase 3 | UNKNOWN |
| NCT03463187 | Phase 1/2 | Completed |
Competing Products
13 competing products in Moderate-to-severe Chronic Plaque Psoriasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine | Pacira Biosciences | Approved | 80 |
| Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + Placebo | Sun Pharmaceutical | Phase 2/3 | 65 |
| SHR-1314 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| SHR-1314 + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Indacaterol + Control | Novartis | Phase 3 | 77 |
| Deucravacitinib | Bristol Myers Squibb | Pre-clinical | 22 |
| Dupilumab + Placebo | Sanofi | Phase 3 | 76 |
| dupilumab | Sanofi | Approved | 84 |
| dupilumab | Sanofi | Pre-clinical | 22 |
| Ponesimod | Vanda Pharmaceuticals | Phase 3 | 69 |
| sufentanil sublingual tablet 30 mcg | Talphera | Phase 3 | 69 |
| Zalviso™ 15 mcg | Talphera | Phase 3 | 69 |
| sufentanil sublingual 30 mcg tablet | Talphera | Phase 3 | 69 |